Welcome to our dedicated page for Ligand Pharma news (Ticker: LGND), a resource for investors and traders seeking the latest updates and insights on Ligand Pharma stock.
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) is a biopharmaceutical company that regularly issues news about its royalty portfolio, technology platforms and capital deployment. The company describes its model as enabling the clinical development of high‑value medicines by providing financing, licensing its technologies, or both, and this approach is reflected in its press releases and investor communications.
News about Ligand often covers financial results and guidance, including updates on total core revenue, royalty revenue, Captisol sales, contract revenue and non‑GAAP measures such as core adjusted earnings per diluted share. The company’s announcements highlight how royalty revenue from partnered products such as Filspari, Ohtuvayre, Capvaxive, Qarziba and Zelsuvmi contributes to its outlook, as well as how deployable capital and new royalty investments are expected to influence long‑term royalty receipts.
Investors following LGND news will also see updates on Ligand’s technology platforms and partner programs. Releases describe Captisol‑enabled approvals like Lasix ONYU, developments in programs such as Qtorin rapamycin, and clinical or regulatory milestones reported by partners that may affect Ligand’s royalty streams. In addition, the company reports on financing transactions, including convertible senior notes offerings and amendments to its credit agreement, which provide context on how Ligand funds royalty acquisitions and other strategic investments.
Corporate events such as Investor Day presentations and participation in healthcare and biopharma conferences are another recurring theme in Ligand’s news flow. These events typically feature discussions of strategy, investment activity, the royalty portfolio and long‑term financial outlook. For investors and observers, the LGND news page offers a centralized view of how Ligand’s royalty‑focused business model, technology licensing and capital allocation decisions evolve over time.
Ligand Pharmaceuticals (Nasdaq: LGND) has announced its senior management team's participation in three upcoming investor conferences in May 2025:
- H.C. Wainwright Royalty Company Conference (Virtual) - Fireside chat on May 13 at 3:30 p.m. ET
- RBC Capital Markets Global Healthcare Conference (New York) - Fireside chat on May 20 at 2:05 p.m. ET
- Craig-Hallum Institutional Investor Conference (Minneapolis) - One-on-one meetings on May 28
Management will be available for one-on-one meetings with investors during all conferences. Interested investors should contact their respective conference representatives to arrange meetings.
Ligand Pharmaceuticals (Nasdaq: LGND) has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results and provide a business update.
The conference call will be accessible via phone at (800) 715-9871 for U.S. & Canada callers and (646) 307-1963 for international participants, using Conference ID 3661098. A live webcast and replay of the call will also be available.
Ligand Pharmaceuticals (NASDAQ: LGND) announced a merger agreement to combine its subsidiary Pelthos Therapeutics with Channel Therapeutics (NYSE: CHRO). The transaction, expected to close in summer 2025, will raise $50 million in equity capital, with Ligand investing $18 million and an investor group led by Murchinson contributing $32 million.
The combined company will operate as Pelthos Therapeutics Inc. (NYSE: PTHS) and focus on commercializing ZELSUVMI™, an FDA-approved prescription medication for Molluscum contagiosum infections. ZELSUVMI is the first home-use treatment approved for patients aged one year and older. Ligand will retain a 13% royalty on worldwide sales.
The merged entity will maintain Channel's NaV 1.7 development programs for chronic pain, eye pain, and post-surgical nerve blocks. Scott Plesha will serve as CEO of the combined company, with Frank Knuettel II as CFO.
Ligand Pharmaceuticals (Nasdaq: LGND) has announced its participation in two major healthcare investor conferences this March 2025. CEO Todd Davis and CFO Tavo Espinoza will represent the company at both events in Miami.
The management team will attend the Leerink Partners Global Healthcare Conference on March 10, engaging in one-on-one meetings with investors. Following this, they will participate in the Barclays 27th Annual Global Healthcare Conference on March 12, where they will join a fireside chat at 12:00 p.m. ET and conduct additional one-on-one meetings.
Investors interested in scheduling individual meetings with Ligand's management should reach out to their Leerink or Barclays representatives to arrange appointments.
Ligand Pharmaceuticals (LGND) reported strong financial results for Q4 and full year 2024, with total revenues reaching $167.1 million for the year. The company saw a 28% growth in royalty revenue, driven by strong performance across major commercial programs.
Q4 2024 revenues were $42.8 million, up 52% from Q4 2023, primarily due to royalty revenue of $34.8 million. However, LGND reported a Q4 GAAP net loss of $31.1 million ($1.64 per share), compared to net income of $18.2 million in Q4 2023.
Key highlights include FDA approvals for three portfolio products with blockbuster potential: Verona's Ohtuvayre, Travere's Filspari, and Merck's Capvaxive. The company reiterated its 2025 guidance of $180-$200 million in revenues and adjusted earnings per share of $6.00-$6.25.
Ligand Pharmaceuticals (Nasdaq: LGND) has announced a $75 million royalty financing agreement with Castle Creek Biosciences to support the Phase 3 clinical study of D-Fi (FCX-007), an autologous gene-modified cell therapy for dystrophic epidermolysis bullosa (DEB). Ligand invested $50 million, leading a syndicate of co-investors who contributed $25 million, in exchange for a high-single digit royalty on worldwide sales of D-Fi. The syndicate includes Paragon Biosciences, Valor Equity Partners, and XOMA Royalty (Nasdaq: XOMA).
D-Fi, an injectable therapy, addresses DEB, a rare genetic skin disorder caused by a mutation in the COL7A1 gene. The therapy uses genetically modified dermal fibroblasts to express COL7 protein, aiding the formation of skin anchoring fibrils. Clinical studies have shown D-Fi to be generally well tolerated, with injection site reactions being the primary adverse effects.
D-Fi has received multiple FDA designations, including Orphan Drug, Rare Pediatric Disease, Fast Track, and Regenerative Medicine Advanced Therapy for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).
Ligand Pharmaceuticals (Nasdaq: LGND) has scheduled its fourth quarter and full year 2024 financial results announcement for Thursday, February 27, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 a.m. ET (5:30 a.m. PT) on the same day to discuss the results and provide a business update. The call will be accessible via phone for U.S. & Canada (800-715-9871) and International (646-307-1963) participants using conference ID 8755336. A live webcast and replay will also be available.
Ligand Pharmaceuticals (Nasdaq: LGND) has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. CEO Todd Davis and CFO Tavo Espinoza will deliver a presentation on February 11, 2025, at 2:40 p.m. Eastern Time.
The company's management team will be available for one-on-one meetings with investors and conference attendees. Interested investors can arrange meetings through their Oppenheimer representative.
Ligand Pharmaceuticals (Nasdaq: LGND) announced its 2025 guidance during its Investor and Analyst Day, projecting total revenue of $180-200 million, representing a 17% increase over 2024. The company expects royalty revenue of $135-140 million, Captisol sales of $35-40 million, and contract revenue of $10-20 million, with core adjusted earnings per diluted share of $6.00-6.25.
The company reaffirmed its 2024 guidance of $160-165 million in total revenue and core adjusted earnings per diluted share of $5.50-5.70. Long-term projections indicate royalty receipts growing at a 22% compound annual growth rate, reaching approximately $285 million by 2029.
Over the past two years, Ligand has deployed $192 million across eight investments and is currently evaluating over $1 billion in actionable opportunities.